JP2016528299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528299A5 JP2016528299A5 JP2016536494A JP2016536494A JP2016528299A5 JP 2016528299 A5 JP2016528299 A5 JP 2016528299A5 JP 2016536494 A JP2016536494 A JP 2016536494A JP 2016536494 A JP2016536494 A JP 2016536494A JP 2016528299 A5 JP2016528299 A5 JP 2016528299A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tumor
- administration
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100031096 Cubilin Human genes 0.000 claims description 5
- 108010003082 intrinsic factor-cobalamin receptor Proteins 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 238000000034 method Methods 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940029329 intrinsic factor Drugs 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 235000019766 L-Lysine Nutrition 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- VWQVUPCCIRVNHF-OIOBTWANSA-N Yttrium-86 Chemical compound [86Y] VWQVUPCCIRVNHF-OIOBTWANSA-N 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229910017052 cobalt Chemical group 0.000 claims 1
- 239000010941 cobalt Chemical group 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229940044173 iodine-125 Drugs 0.000 claims 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- QCWXUUIWCKQGHC-YPZZEJLDSA-N zirconium-89 Chemical compound [89Zr] QCWXUUIWCKQGHC-YPZZEJLDSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 2
- 102000011409 Transcobalamins Human genes 0.000 description 1
- 108010023603 Transcobalamins Proteins 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868841P | 2013-08-22 | 2013-08-22 | |
| US61/868,841 | 2013-08-22 | ||
| PCT/US2014/052381 WO2015027205A1 (en) | 2013-08-22 | 2014-08-22 | Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528299A JP2016528299A (ja) | 2016-09-15 |
| JP2016528299A5 true JP2016528299A5 (enExample) | 2017-09-28 |
Family
ID=52484208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536494A Pending JP2016528299A (ja) | 2013-08-22 | 2014-08-22 | ビタミンｂ１２および内因子を含む組成物およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160199500A1 (enExample) |
| EP (1) | EP3036008A4 (enExample) |
| JP (1) | JP2016528299A (enExample) |
| CA (1) | CA2921507A1 (enExample) |
| WO (1) | WO2015027205A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105849568B (zh) | 2013-11-14 | 2018-05-04 | 恩多塞特公司 | 用于正电子发射断层术的化合物 |
| US20180154007A1 (en) * | 2015-05-20 | 2018-06-07 | Syracuse University | Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist |
| KR20210003135A (ko) | 2018-04-17 | 2021-01-11 | 엔도사이트, 인코포레이티드 | 암의 치료 방법 |
| WO2020113130A1 (en) * | 2018-11-29 | 2020-06-04 | The Trustees Of Dartmouth College | Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy |
| WO2020236903A1 (en) * | 2019-05-20 | 2020-11-26 | Syracuse University | Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206 |
| JP7604397B2 (ja) | 2019-05-20 | 2024-12-23 | エンドサイト・インコーポレイテッド | Ｐｓｍａコンジュゲートの調製方法 |
| WO2025072713A1 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Polymyxins for delivery of agents to the kidney |
| WO2025072672A2 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Slc6a19-targeting modulatory nucleic acid agents |
| AU2024348221A1 (en) | 2023-09-27 | 2026-04-30 | Judo Bio Inc. | Aminoglycosides for delivery of agents to the kidney |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB733875A (en) * | 1951-12-20 | 1955-07-20 | Organon Nv | Process for the manufacture of therapeutically active preparations |
| US5574018A (en) * | 1994-07-29 | 1996-11-12 | Amgen Inc. | Conjugates of vitamin B12 and proteins |
| EP1435973A4 (en) * | 2001-09-28 | 2007-05-02 | Mayo Foundation | SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS |
| EP1441773A1 (en) * | 2001-10-19 | 2004-08-04 | Thomas Jefferson University | Pacap compositions and methods for tumor imaging and therapy |
| WO2004084953A1 (en) * | 2003-03-24 | 2004-10-07 | Schering Ag | Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics |
| WO2006071754A2 (en) * | 2004-12-23 | 2006-07-06 | Purdue Research Foundation | Positron emission tomography imaging method |
| JP2006350686A (ja) * | 2005-06-16 | 2006-12-28 | Seiko Epson Corp | 命令セット・シミュレータ生成装置及びシミュレータ生成方法 |
| US20110092416A1 (en) * | 2007-03-05 | 2011-04-21 | Robert Patrick Doyle | Vitamine B12 - Peptide Conjugates for Oral Delivery |
| AU2008223431B2 (en) * | 2007-03-05 | 2013-06-13 | Syracuse University | A conjugate of insulin and vitamin B12 for oral delivery |
| US20140161813A1 (en) * | 2012-12-12 | 2014-06-12 | Bauer Research Foundation | Methods for the diagnosis, treatment and monitoring of cancer |
-
2014
- 2014-08-22 CA CA2921507A patent/CA2921507A1/en not_active Abandoned
- 2014-08-22 US US14/913,587 patent/US20160199500A1/en not_active Abandoned
- 2014-08-22 JP JP2016536494A patent/JP2016528299A/ja active Pending
- 2014-08-22 WO PCT/US2014/052381 patent/WO2015027205A1/en not_active Ceased
- 2014-08-22 EP EP14837434.1A patent/EP3036008A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | αVβ3 Integrin-targeted radionuclide therapy with 64Cu-cyclam-RAFT-c (-RGDfK-) 4 | |
| US20200123216A1 (en) | Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | |
| CA3174263A1 (en) | Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease | |
| Batra et al. | Preclinical development of [211At] meta-astatobenzylguanidine ([211At] MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma | |
| Tsiapa et al. | Biological evaluation of an ornithine-modified 99mTc-labeled RGD peptide as an angiogenesis imaging agent | |
| WO2007117467B1 (en) | Use of tm-601 for the diagnosis and treatment of tumors | |
| Ogawa et al. | Evaluation of Ga-DOTA-(D-Asp) n as bone imaging agents: D-aspartic acid peptides as carriers to bone | |
| Bodei et al. | Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. | |
| JP2019533728A (ja) | 放射線治療及び画像診断のための製剤 | |
| Zhang et al. | Targeted radiotherapy with tumor vascular homing trimeric GEBP11 peptide evaluated by multimodality imaging for gastric cancer | |
| JP2017503763A5 (enExample) | ||
| Qin et al. | Dimeric FAPI with potential for tumor theranostics | |
| Chakravarty et al. | 90Y/177Lu‐labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation | |
| Higuchi et al. | Norepinephrine transporter–targeted cancer theranostics—new horizons | |
| Chen et al. | In vivo examination of 188Re (I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer | |
| Pandey et al. | 99mTc carbonyl DTPA–Rituximab: Preparation and preliminary bioevaluation | |
| KR102061366B1 (ko) | 환자 선정방법 | |
| Ranjbar et al. | Development of 153Sm/177Lu-EDTMP as a possible therapeutic complex | |
| Musket et al. | The application of radionuclide therapy for breast cancer | |
| Chérel et al. | Alpha emitting radionuclides and radiopharmaceuticals for therapy | |
| Chen et al. | Biodistribution, pharmacokinetics and efficacy of 188Re (I)-tricarbonyl-labeled human serum albumin microspheres in an orthotopic hepatoma rat model | |
| Olsen et al. | Novel radioisotope-based nanomedical approaches | |
| Ha et al. | Synthesis and evaluation of a radioiodinated bladder cancer specific peptide | |
| Fozing et al. | Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer | |
| US12629432B2 (en) | Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease |